Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 9/20 | 0.43 |
| ▸ | VEGFA | P15692 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30336282 | 1.00 | GRM5 (0.47) | GRM5ALDH1A1CHRNB2CHRNA4EPAS1 | |
| SCHEMBL202404 | 0.87 | ALDH1A1 (0.61) | GRM5ALDH1A1 | |
| SCHEMBL509576 | 0.84 | ALDH1A1 (0.58) | GRM5ALDH1A1 | |
| SCHEMBL168353 | 0.82 | ALDH1A1 (0.69) | ALDH1A1NQO2 | |
| SCHEMBL16960842 | 0.79 | ALDH1A1 (0.40) | GRM5ALDH1A1CHRNB2CHRNA4EPAS1 | |
| SCHEMBL16961090 | 0.79 | ALDH1A1 (0.40) | GRM5ALDH1A1CHRNB2CHRNA4NQO2 | |
| SCHEMBL27774310 | 0.79 | CHRNB2 (0.41) | GRM5ALDH1A1CHRNB2CHRNA4EPAS1 | |
| SCHEMBL24086878 | 0.79 | EPAS1 (0.40) | EPAS1VEGFA | |
| SCHEMBL13570675 | 0.79 | DHFR (0.43) | EPAS1 | |
| SCHEMBL1584993 | 0.78 | EPAS1 (0.40) | EPAS1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174616-A1 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4326257-A1 | AZETIDINYL-ACETAMIDES AS CXCR7 INHIBITORS | ChemoCentryx, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230203059-A1 | MACROCYCLIC JAK INHIBITOR AND USES THEREOF | BIOPOLAR HONGYE (NANTONG) PHARMACEUTICAL CO. LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| CN-116322759-A | Phospholipid compounds and uses thereof | 吉利德科学公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4159738-A1 | MACROCYCLIC JAK INHIBITOR AND USES THEREOF | Biopolar Hongye (Guangdong) Pharmaceutical Co. Ltd (CN) | 2023-04-05 | — | — | EP | disclosed |
| US-20230050653-A1 | ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-02-16 | — | — | US | disclosed |
| US-20230050653-A1 | ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-02-16 | — | — | US | disclosed |
| US-20220348568-A1 | AZETIDINYL-ACETAMIDES AS CXCR7 INHIBITORS | INC., CHEMOCENTRYX | 2022-11-03 | — | — | US | disclosed |
| WO-2022225832-A1 | AZETIDINYL-ACETAMIDES AS CXCR7 INHIBITORS | CHEMOCENTRYX, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| EP-4059928-A1 | ROCK INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2022-09-21 | — | — | EP | disclosed |
| CN-1649865-A | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMA INC (US) | 2005-08-03 | — | — | CN | disclosed |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| EP-1379525-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2004-01-14 | — | — | EP | disclosed |
| EP-1377556-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | Pfizer Limited (GB) | 2004-01-07 | — | — | EP | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002085860-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LIMITED (GB) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002068417-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348568-A1 | AZETIDINYL-ACETAMIDES AS CXCR7 INHIBITORS | CXCR1, CXCR5, CXCR6 | GRM5 1977/4885ALDH1A1 622/4885CHRNB2 1733/4885 |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | GRM5 8/4885ALDH1A1 3466/4885CHRNB2 117/4885 |
| US-20240174616-A1 | HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | GRM5 597/4885ALDH1A1 922/4885CHRNB2 1279/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | GRM5 8/4885ALDH1A1 3466/4885CHRNB2 117/4885 |
| US-20230203059-A1 | MACROCYCLIC JAK INHIBITOR AND USES THEREOF | JAK3, JAK2, JAK1 | GRM5 1687/4885ALDH1A1 4145/4885CHRNB2 4883/4885 |
| US-20230050653-A1 | ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | ROCK1, CYP11B1, CYP4A11 | GRM5 4595/4885ALDH1A1 860/4885CHRNB2 3980/4885 |
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | GRM5 2894/4885ALDH1A1 385/4885CHRNB2 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.